ANX-M1 (Human IgG1)
Based on 1 Customer Validation
ANX-M1 is a blood-brain barrier-permeable anti-C1q antibody. ANX-M1 can slow down the progression of retinal degeneration following photo-oxidative damage. ANX-M1 has been incorporated into nanocarriers to evaluate its brain delivery efficacy in a mouse model of Alzheimer's disease. ANX-M1 is applicable for research on age-related macular degeneration and Alzheimer's disease [1].
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.0%
- 분자량:145.78 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human/Mouse
IC50 & Target
|
C1q |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (adult, postnatal day 60-90, equal numbers of male and female, photo-oxidative damage-induced retinal degeneration)[1]
-
Dosage:7.5 μg/μL (intravitreal post-treatment); 7.5 μg/μL (intravitreal pre-treatment); 100 mg/kg (systemic)
-
Administration:intravitreal (single dose on day 7 or day 0); intraperitoneal (days 0,4,8)
-
Result:Significantly reduced TUNEL+ photoreceptor cell death at day 14 compared to IgG control (P < 0.05), significantly increased outer nuclear layer (ONL) thickness (P < 0.05), significantly improved rod a-wave and b-wave electroretinography (ERG) responses (P < 0.05, most pronounced at 1.9 log cd.s/m²), and significantly improved cone ERG responses (P < 0.05) with intravitreal post-treatment; showed no significant differences in TUNEL+ cell count, ONL thickness, IBA1+ cell count, or ERG responses compared to IgG control (P > 0.05) with intravitreal pre-treatment; reduced serum complement hemolytic activity by >50% at day 12 (P < 0.05) but showed no significant differences in TUNEL+ cell count, ONL thickness, IBA1+ cell count, or ERG responses compared to IgG control (P > 0.05) with systemic administration
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
-
Flow cytometric analysis of 1X106 Hela cells labeling C1q with ANX-M1 (HY-P991886, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
Appearance Liquid
-
분자량 145.78 kDa
-
Color Colorless to light yellow
-
SMILES
[ANX-M1 (Human IgG1)]
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Jiao H, et al. Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration. Mol Neurodegener. 2018;13(1):45. Published 2018 Aug 20. [Content Brief]
[2]. Gagnon M, et al. Evaluation of Novel B1R/B2R Agonists Containing TRIOZAN™ Nanoparticles for Targeted Brain Delivery of Antibodies in a Mouse Model of Alzheimer Disease. Molecules. 2023;28(13):5206. Published 2023 Jul 4. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- ANX-M1 (Human IgG1)
- Complement System
- TUNEL+ photoreceptor cell death
- C57BL/6J mice
- C1q inhibitor
- age-related macular degeneration
- intravitreally
- classical complement pathway activation
- blood-brain barrier
- ERG responses
- B6C3-Tg (APPswe/PSEN1dE9) mice
- retinal degeneration
- serum complement hemolytic activity
- B1R/B2R agonist-functionalized TRIOZAN? nanoparticles
- ONL thickness
- Alzheimer’s disease
- C1q
- Alzheimer disease
- mouse
- photo-oxidative damage
- TRIOZAN? NPs
- anti-C1q monoclonal antibody
- Inhibitor
- inhibitor
- inhibit